Access
This article is part of Nature's premium content.
Published online 7 February 2007 | Nature | doi:10.1038/news070205-7
News
Genetic test gets approval
United States gives thumbs up to breast cancer prognostic.
US regulators have approved a new diagnostic tool to help target treatment for breast cancer patients.
The test, called MammaPrint and produced by the Dutch company Agendia, uses the expression of 70 genes in tumour samples to help determine whether a woman with early-stage cancer is likely to suffer from a recurrence, and so whether she will benefit from chemotherapy or not.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
There are currently no comments.
